Surgery
Volume 148, Issue 3 , Pages 499-509 , September 2010

Topical nanoemulsion therapy reduces bacterial wound infection and inflammation after burn injury

  • Mark R. Hemmila, MD

      Affiliations

    • Department of Surgery, University of Michigan Medical School, Ann Arbor, MI
    • Corresponding Author InformationReprint requests: Mark R. Hemmila, MD, Trauma Burn Center, University of Michigan Health System, 1B407 University Hospital, 1500 E. Medical Center Drive, SPC 5033, Ann Arbor, MI 48109-5033.
    • ,
  • Aladdein Mattar, MD

      Affiliations

    • Department of Surgery, University of Michigan Medical School, Ann Arbor, MI
    • ,
  • Michael A. Taddonio, BS

      Affiliations

    • Department of Surgery, University of Michigan Medical School, Ann Arbor, MI
    • ,
  • Saman Arbabi, MD

      Affiliations

    • Department of Surgery, University of Washington Medical School, Seattle, WA
    • ,
  • Tarek Hamouda, MD, PhD

      Affiliations

    • NanoBio Corporation, Ann Arbor, MI
    • ,
  • Peter A. Ward, MD

      Affiliations

    • Department of Pathology, University of Michigan Medical School, Ann Arbor, MI
    • ,
  • Stewart C. Wang, MD, PhD

      Affiliations

    • Department of Surgery, University of Michigan Medical School, Ann Arbor, MI
    • ,
  • James R. Baker Jr., MD

      Affiliations

    • Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI
    • NanoBio Corporation, Ann Arbor, MI

,Accepted 8 January 2010.

References 

  1. Bessey PQ. Wound care. In:  Herndon DN editors. Total burn care. 3rd ed.. Philadelphia: Elsevier; 2007;p. 127–135
  2. Steinstraesser L, Tack BF, Waring AJ, Hong T, Boo LM, Fan MH, et al. Activity of novispirin G10 against Pseudomonas aeruginosa in vitro and in infected burns. Antimicrob Agents Chemother. 2002;46:1837–1844
  3. Barton RG, Saffle JR, Morris SE, Mone M, Davis B, Shelby J. Resuscitation of thermally injured patients with oxygen transport criteria as goals of therapy. J Burn Care Rehabil. 1997;18(1 Pt 1):1–9
  4. Hamouda T, Hayes MM, Cao Z, Tonda R, Johnson K, Wright DC, et al. A novel surfactant nanoemulsion with broad-spectrum sporicidal activity against Bacillus species. J Infect Dis. 1999;180:1939–1949
  5. Hamouda T, Myc A, Donovan B, Shih AY, Reuter JD, Baker JR. A novel surfactant nanoemulsion with a unique non-irritant topical antimicrobial activity against bacteria, enveloped viruses and fungi. Microbiol Res. 2001;1561:1–7
  6. Hamouda T, Baker JR. Antimicrobial mechanism of action of surfactant lipid preparations in enteric Gram-negative bacilli. J Appl Microbiol. 2000;89:397–403
  7. Myc A, Vanhecke T, Landers JJ, Hamouda T, Baker JR. The fungicidal activity of novel nanoemulsion (X8W60PC) against clinically important yeast and filamentous fungi. Mycopathologia. 2001;155:195–201
  8. Michigan Nanotechnology Institute for Medicine and Biological Sciences [NIMBS Web site]. Antimicrobial nanoemulsions. Available at: http://nano.med.umich.edu/Platforms/Antimicrobial-Nanoemulsion.html. Accessed October 21, 2009.
  9. Neal GD, Lindholm GR, Lee MJ, Marvin JA, Heimbach DM. Burn wound histologic culture–a new technique for predicting burn wound sepsis. J Burn Care Rehabil. 1981;2:35–39
  10. Taddonio TE, Thomson PD, Tait MJ, Prasad JK, Feller I. Rapid quantification of bacterial and fungal growth in burn wounds: biopsy homogenate Gram stain versus microbial culture results. Burns Incl Therm Inj. 1988;14:180–184
  11. Uppal SK, Ram S, Kwatra B, Garg S, Gupta R. Comparative evaluation of surface swab and quantitative full thickness wound biopsy culture in burn patients. Burns. 2007;33:460–463
  12. Steinstraesser L, Föhn M, Klein RD, Aminlari A, Remick DG, Su GL, et al. Feasibility of biolistic gene therapy in burns. Shock. 2001;15:272–277
  13. Ipaktchi K, Mattar A, Niederbichler AD, Hoesel LM, Hemmila MR, Su GL, et al. Topical p38MAPK inhibition reduces dermal inflammation and epithelial apoptosis in burn wounds. Shock. 2006;26:201–209
  14. Lyons A, Goebel A, Mannick JA, Lederer JA. Protective effects of early interleukin 10 antagonism in injury-induced immune dysfunction. Arch Surg. 1999;134:1317–1323
  15. Varedi M, Jeschke MG, Englander EW, Herndon DN, Barrow RE. Serum TGF-beta in thermally injured rats. Shock. 2001;16:380–382
  16. Huang Z, Pereira C, Toliver-Kinsky T, Murphey ED, Varma TK, Lin CY, et al. Effect of transforming growth factor-beta neutralization on survival and bacterial clearance in a murine model of Pseudomonas aeruginosa burn wound infection. J Burn Care Res. 2006;27:682–687
  17. Steinstraesser L, Klein RD, Aminlari A, Fan MH, Khilanani V, Remick DG, et al. Protegrin-1 enhances bacterial killing in thermally injured skin. Crit Care Med. 2001;29:1431–1437
  18. Hansbrough JF, Wikstrom T, Braide M, Tenenhaus M, Rennekampff OH, Kiessig V, et al. Neutrophil activation and tissue neutrophil sequestration in a rat model of thermal injury. J Surg Res. 1996;61:17–22
  19. Piccolo MT, Wang Y, Verbrugge S, Warner RL, Sannomiya P, Piccolo NS, et al. Role of chemotactic factors in neutrophil activation after thermal injury in rats. Inflammation. 1999;23:371–385
  20. Till GO, Johnson KJ, Kunkel R, Ward PA. Intravascular activation of complement and acute lung injury: dependency on neutrophils and toxic oxygen metabolites. J Clin Invest. 1982;69:1126–1135
  21. Ipaktchi K, Mattar A, Niederbichler AD, Hoesel LM, Vollmannshauser S, Hemmila MR, et al. Topical p38 MAPK inhibition reduces bacterial growth in an in vivo burn wound model. Surgery. 2007;142:86–93
  22. Ipaktchi K, Mattar A, Niederbichler AD, Hoesel LM, Vollmannshauser S, Hemmila MR, et al. Attenuating burn wound inflammatory signaling reduces systemic inflammation and acute lung injury. J Immunol. 2006;177:8065–8071
  23. Ipaktchi K, Mattar A, Niederbichler AD, Kim J, Hoesel LM, Hemmila MR, et al. Attenuating burn wound inflammation improves pulmonary function and survival in a burn-pneumonia model. Crit Care Med. 2007;35:2139–2144
  24. Hoesel LM, Mattar A, Arbabi S, Niederbichler AD, Ipaktchi K, Su GL, et al. Local wound p38 MAPK inhibition attenuates burn-induced cardiac dysfunction Surgery. 2009;146:775–785
  25. Jones T, Ijzerman MM, Flack MR, Baker JR Jr. Subject-assessed time to healing in a randomized double-blind, vehicle-controlled trial of a novel topical antiviral nanoemulsion (NB-001) for recurrent Herpes labialis. In Programs and abstracts of the 48th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy; October 25-28, 2008; Washington, DC. Abstract V-3771.
  26. NanoBio Corporation successfully completes Phase 2b study in Herpes labialis. NanoBio Corporation home page on the Internet. Available at: http://nanobio.com/News/NB-00X_Herpes2b.html. Accessed October 21, 2009.
  27. Jarrat M, Ijzerman MM, Flack MR, Baker JR Jr. Safety, tolerability and pharmacokinetics of NB-001 in a phase 2 dose ranging trial in subjects with recurrent Herpes labialis. In Programs and abstracts of the 48th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy; October 25-28, 2008; Washington, DC. Abstract V-3539.
  28. Ciotti S, Eisma R, Ma L, Baker JR Jr. Novel nanoemulsion NB-001 permeates skin by the follicular route. In Programs and abstracts of the 48th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy; October 25-28, 2008; Washington, DC. Abstract A-1898.

 Supported in part by research grants from the National Institutes of Health (K08-GM078610 to M.R.H.) and joint support from the American College of Surgeons and the American Association for the Surgery of Trauma (to M.R.H.)

 James R. Baker Jr, MD, is the Executive Chairman and Chief Executive Officer of NanoBio Corporation, Ann Arbor, MI; Tarek Hamouda, MD, PhD, is the Director of Vaccine Research for NanoBio Corporation, Ann Arbor, MI.

PII: S0039-6060(10)00007-3

doi: 10.1016/j.surg.2010.01.001

Surgery
Volume 148, Issue 3 , Pages 499-509 , September 2010

Article Tools

* Image Usage & Resolution